Spero Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Spero Therapeutics, Inc. (SPRO) had Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations of $50.77 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations · last filed 2026-08-12
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $50.77M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $56.13M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $40.27M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations $48.62M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations |
|---|---|
| 2026-06-30 | $50.77M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $56.13M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $40.27M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $48.62M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $31.19M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $48.89M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $52.89M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $76.29M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $63.53M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $82.27M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $76.33M 10-K · filed 2026-03-26 |
| 2023-09-30 | $93.83M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $77.69M 10-Q · filed 2024-08-05 |
| 2023-03-31 | $96.25M 10-Q · filed 2024-05-15 |
| 2022-12-31 | $109.11M 10-K · filed 2025-03-27 |
| 2022-09-30 | $50.45M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $45.40M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $72.11M 10-Q · filed 2023-05-11 |
| 2021-12-31 | $112.58M 10-K · filed 2024-03-13 |
| 2021-09-30 | $112.86M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $71.56M 10-Q · filed 2022-08-10 |
| 2021-03-31 | $77.04M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $85.21M 10-K · filed 2023-03-30 |
| 2020-09-30 | $125.24M 10-Q · filed 2021-11-10 |
| 2020-06-30 | $65.34M 10-Q · filed 2021-08-05 |
| 2020-03-31 | $64.36M 10-Q · filed 2021-05-06 |
| 2019-12-31 | $29.73M 10-K · filed 2022-03-31 |
| 2019-09-30 | $45.60M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $71.13M 10-Q · filed 2020-08-06 |
| 2019-03-31 | $49.40M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $34.08M 10-K · filed 2021-03-11 |
| 2018-09-30 | $40.48M 10-Q · filed 2019-11-04 |
| 2018-06-30 | $48.72M 10-Q · filed 2019-08-08 |
| 2018-03-31 | $52.55M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $87.34M 10-K · filed 2020-03-16 |
| 2017-09-30 | $25.42M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $36.35M 10-Q · filed 2018-08-09 |
| 2016-12-31 | $10.37M 10-K · filed 2019-03-14 |
| 2015-12-31 | $5.74M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |